Clinical Trials Logo

Clinical Trial Summary

The investigators propose that pharmacist interventions would reduce the amount of unresolved medication-related problems in hemodialysis patients.

Condition:Hemodialysis patients

Intervention:Behavioral,Pharmacist intervention

Study Design:Randomized Allocation

Control: Active Control

Endpoint Classification: Efficacy Study

Intervention Model: Parallel Assignment

Masking: Double Blind (Caregiver, Outcomes Assessor)

Primary Purpose: Treatment


Clinical Trial Description

Introduction:

End stage renal disease (ESRD) incidence in Taiwan ranked first and prevalence ranked second in the world from 2002 to 2005. Several foreign researches had reported that hemodialysis (HD) patients often require 12 medications to treat 5 to 6 comorbid conditions. Besides, ESRD is a lifelong disease and rates of compliance may diminish overtime. Thus, HD patients may be at particular risk for drug related problems, durg-drug interactions and noncompliance. Our aim is to analysis the effect of pharmacist in medication-related problems in ambulatory hemodialysis patients.

Methods:

This study is a randomized double-blind, active controlled trial. The investigators will invite and communicate with HD patients to find medication -related problems. After pharmacist evaluation, pharmacist will do pharmaceutical interventions to resolve medication-related problems, drug-drug interactions etc. in experimental group. In the active control group, pharmacist in this study will not do pharmaceutical interventions. The investigators will monitor each patient in a two-week period for medication-related problems.

Our primary outcome is the amount of unresolved medication-related problems in each group after two weeks. Blind outcome assessor will evaluate the amount of unresolved medication-related problems in each case as well as compliance in these patients after two weeks.

The investigators suppose that clinical pharmaceutical intervention will reduce the amount of unresolved medication-related problem in experimental group. On the other hand, patients without clinical pharmaceutical intervention will have more unresolved medication-related problems. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Health Services Research


Related Conditions & MeSH terms


NCT number NCT01356563
Study type Interventional
Source Sin-Lau Hospital
Contact
Status Recruiting
Phase N/A
Start date May 2011
Completion date May 2012

See also
  Status Clinical Trial Phase
Completed NCT01947673 - Mechanisms of Intradialytic Hypertension N/A
Not yet recruiting NCT03634904 - Serum Ceftazidime Concentrations in Hemodialysis Patients N/A
Terminated NCT01982864 - Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients. Phase 4
Completed NCT01448174 - Salusin-alpha - a New Factor in the Pathogenesis of Lipid Abnormalities in Hemodialysis Patients Phase 4
Completed NCT01421771 - Blood Pressure in Dialysis Patients N/A
Completed NCT01722695 - Performance Comparison of Revaclear With Larger Dialyzer N/A
Withdrawn NCT01015313 - Effects of Intensified Sodium Management in Hemodialysis Patients N/A
Not yet recruiting NCT02452788 - Pharmaceutical Care in Ambulatory Hemodialysis Patients N/A
Completed NCT02259413 - Effect of an Exercise Rehabilitation Program on Symptoms in Hemodialysis N/A
Completed NCT01181544 - A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis N/A
Completed NCT01320202 - Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients Phase 3
Completed NCT02285075 - Temocillin Pharmacokinetic in Hemodialysis Phase 4
Completed NCT02825589 - BIA-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients N/A
Completed NCT00890045 - Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency Study N/A
Not yet recruiting NCT02264964 - Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis N/A
Terminated NCT01312441 - Sustainability of Vitamin D Levels After Repletion With Ergocalciferol In Chronic Kidney Disease Stage 5D Phase 4
Completed NCT01214928 - Hemodialysis Vitamin D Pilot N/A
Completed NCT00967993 - Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease Phase 2
Completed NCT01981603 - Transplant Navigator Dissemination N/A
Completed NCT01578421 - Investigation on the Middle Size Molecule Elimination Characteristics of the FXCorDiax 100 in Relation to the FX 100 and the Polyflux 210 H Dialyser N/A